Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Karl Swedberg

Senior Professor

Karl Swedberg
Senior Professor
karl.swedberg@gu.se

Room number: 1319
Postal Address: SU Sahlgrenska, 41345 Göteborg
Visiting Address: Wallenberglab/su , Göteborg


Institute of Medicine (More Information)
Box 428
405 30 Göteborg
www.medicine.gu.se
medicin@gu.se
Fax: +46 31823925
Visiting Address: Medicinaregatan 3, plan 5 , 413 90 Göteborg

About Karl Swedberg

Karl Swedberg, MD, PhD, FESC, is Senior Professor of Cardiology and Care Science, Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden. He is a Scientific Advisor to the University of Gothenburg Centre for Person Centred Care (GPCC).

He was the first to report on survival benefits of a beta-blocker (1979), an ACE-inhibitor (1987), an angiotensinreceptor blocker (2003) and recently an ARNI (angiotensin receptor antagonist and neprilysin inhibitor 2014) in chronic heart failure. He has published widely in international journals with more than 600 publications in peer-reviewed journals, 340 original research papers and > 65000 citations.

He was Chairman of the Task Force on the Diagnosis and Treatment of Chronic Heart Failure that updated the ESC Guidelines 2005. He has participated in Steering Committees in numerous outcome trials in myocardial infarction and heart failure.

Rewards and distinctions

  • Recipient of the 2004 Kaufman Award of heart failure research from Cleveland Clinics, USA.
  • Awarded European Society of Cardiology (ESC) Gold medal 2007 for outstanding contributions to the cardiovascular field.
  • He gave the Paul Dudley White international lecture, AHA annual meeting in Orlando 2009.
  • "Lifetime Achievement Award" from Heart Failure Association (HFA) of ESC in 2016.
  • Member of the Editorial Board of several international journals.
  • 2005-2009 he served as Editor-in-Chief of the European Journal of Heart Failure.
  • He is Associate Editor in European Heart Journal since 2012.
  • Among Highly cited 2017-2019 https://publons.com/researcher/2889721/karl-swedberg/

 

Latest publications

Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction
R. Rørth, P. S. Jhund, M. B. Yilmaz, S. L. Kristensen, P. Welsh et al.
Circulation. Heart failure, Journal article 2020
Journal article

The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE
P. Dewan, A. Jackson, P. S. Jhund, L. Shen, J. P. Ferreira et al.
European Journal of Heart Failure, Journal article 2020
Journal article

Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction.
Kieran F Docherty, Li Shen, Davide Castagno, Mark C Petrie, William T Abraham et al.
European journal of heart failure, Journal article 2020
Journal article

Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Scott D Solomon, Muthiah Vaduganathan, Brian L Claggett, Milton Packer, Michael Zile et al.
Circulation, Journal article 2020
Journal article

Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction
P. Rossignol, K. Duarte, N. Girerd, M. Karoui, J. J. V. McMurray et al.
European Journal of Heart Failure, Journal article 2020
Journal article

Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.
Nadia Bouabdallaoui, Eileen O'Meara, Virginie Bernier, Michel Komajda, Karl Swedberg et al.
ESC heart failure, Journal article 2019
Journal article

Showing 41 - 50 of 433

2018

Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis
M. Komajda, M. Bohm, J. S. Borer, I. Ford, L. Tavazzi et al.
European Journal of Heart Failure, Journal article 2018
Journal article

Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
Emil Wolsk, Brian Claggett, Lars Køber, Stuart Pocock, Salim Yusuf et al.
European journal of heart failure, Journal article 2018
Journal article

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF
U. M. Mogensen, L. Kober, P. S. Jhund, A. S. Desai, M. Senni et al.
European journal of heart failure, Journal article 2018
Journal article

Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure A Secondary Analysis of the PARADIGM-HF Trial
A. Chandra, E. F. Lewis, B. L. Claggett, A. S. Desai, M. Packer et al.
Jama Cardiology, Journal article 2018
Journal article

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure
K. Damman, M. Gori, B. Claggett, P. S. Jhund, M. Senni et al.
Jacc-Heart Failure, Journal article 2018
Journal article

Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: Recurrent hospitalizations and mortality
Elke Platz, Pardeep S. Jhund, Brian L. Claggett, Marc A. Pfeffer, Karl Swedberg et al.
European Journal of Heart Failure, Journal article 2018
Journal article

Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study
P. Welsh, L. Kou, C. Yu, I. Anand, D. J. van Veldhuisen et al.
European journal of heart failure, Journal article 2018
Journal article

Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT
M. Bohm, M. Komajda, J. S. Borer, I. Ford, C. Maack et al.
European journal of heart failure, Journal article 2018
Journal article

Showing 41 - 50 of 433

Page Manager: Karin Allander|Last update: 10/1/2019
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?